For the quarter ending 2026-03-31, CBIO has $199,130K in assets. $15,283K in debts. $189,163K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 189,163 | 213,192 | 133,265 | - |
| Accounts receivable, net | 0 | 18,000 | - | - |
| Prepaid expenses and other current assets | 6,400 | 5,463 | 1,298 | 1,582 |
| Cash | - | - | - | 152,645 |
| Total current assets | 195,563 | 236,655 | 134,563 | 154,227 |
| Property and equipment, net | 929 | 846 | 782 | 193 |
| Operating lease right-of-use assets | 1,372 | 1,469 | 1,564 | 1,607 |
| Restricted cash | 107 | 107 | 107 | 106 |
| Other assets | 1,159 | 1,216 | 1,253 | 1,300 |
| Total assets | 199,130 | 240,293 | 138,269 | 157,433 |
| Accounts payable-Nonrelated Party | 1,190 | 9,997 | 2,561 | 1,648 |
| Warrant liability, related party | - | 0 | 2,088 | 2,096 |
| Accrued expenses and other current liabilities-Nonrelated Party | - | 16,344 | 8,965 | 7,608 |
| Accrued expenses and other current liabilities | 4,433 | - | - | - |
| Related party accounts payable and other current liabilities-Related Party | 0 | 140 | 6,273 | 5,183 |
| Deposit liability | 5,000 | 5,000 | - | - |
| Deferred revenue | 3,117 | 4,156 | - | - |
| Operating lease liability, current | 453 | 435 | 417 | 211 |
| Total current liabilities | 14,193 | 36,072 | 20,304 | 16,746 |
| Operating lease liability, noncurrent | 1,090 | 1,209 | 1,324 | 1,433 |
| Notes payable, noncurrent | - | 0 | 0 | 0 |
| Total liabilities | 15,283 | 37,281 | 21,628 | 18,179 |
| Series a non-voting convertible preferred shares, 0.001 par value 2,890 shares and no shares authorized as of december 31, 2025 and december 31, 2024, respectively 2,890 shares and no shares issued and outstanding as of december 31, 2025 and december 31, 2024, respectively-Series APreferred Stock | - | 4,000 | 4,000 | 4,000 |
| Non-voting convertible preferred shares, 0.001 par value 5,000,000 shares authorized as of march31, 2026 and december31, 2025 2,890 series a designated shares issued and outstanding as of march31, 2026 and december31, 2025 | 4,000 | - | - | - |
| Ordinary shares, 0.001 par value 175,000,000 shares authorized as of march31, 2026 and december31, 2025, 27,571,935 and 27,556,767 shares issued and outstanding as of march31, 2026 and december31, 2025, respectively | 28 | 28 | 14 | 14 |
| Additional paid-in capital | 374,911 | 370,793 | 192,039 | 190,045 |
| Accumulated deficit | -195,092 | -171,809 | -79,412 | -54,805 |
| Total shareholders' equity | 183,847 | 203,012 | 116,641 | 139,254 |
| Total liabilities, convertible preferred shares, and shareholders equity | 199,130 | 240,293 | 138,269 | 157,433 |
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)